Polymorphisms in Genes of Cytokines and Matrix Metalloproteinases Associated With Ischemic Heart Disease in Patients With Type 2 Diabetes

Objective. To examine associations between ischemic heart disease (IHD) and polymorphisms in cytokine genes (IL-1B, IL-4, IL-6, IL-10, TNFA, VEGF) and matrix metalloproteinase genes (MMP2, MMP3, MMP9) in patients with type 2 diabetes. Material and methods. We studied 232 Caucasian diabetic subjects (33 men and 199 women aged 50-70 years). In 93 patients IHD was verified by treadmill test and/or coronary angiography (86 subjects with stable angina, 19 with previous myocardial infarction). Thirteen polymorphisms localized in the promoters of IL-1B (rs1143627), IL-4 (rs2243250), IL-6 (rs1800795), IL-10 (rs1800872, rs1800896), TNFA (rs361525, rs1800629, rs1800630), VEGF (rs699947, rs3025039), MMP2 (rs243865), MMP3 (rs3025058) and MMP9 (rs3918242) were investigated. Results. Prevalence of G-allele and GG-genotype at -308 position of TNFA (rs1800629), as well as C-allele and CC-genotype at position +936 of VEGF (rs3025039) was higher in patients with IHD as compared to patients without IHD (0R=2.0, OR=2.2, OR=2.1, 0R=2.4, respectively, all p=0.02). In logistic regression analysis, TNFA -308 A/ G and VEGF +936 C/T polymorphisms showed associations with IHD (both p=0.009). These polymorphisms along with age, body mass index, duration of diabetes, low density and high density lipoprotein cholesterol were associated with IHD in multivariate models (p=0.0002 and p=0.00008, respectively). Nine combinations of TNFA -308 GG-genotype and variants of other genes demonstrated associations with IHD (p<0.002). Conclusion. The polymorphisms in promoter regions of TNFA (rs1800629) and VEGF (rs3025039) are associated with IHD in patients with type 2 diabetes.

ишемическая болезнь сердца, сахарный диабет, полиморфизм гена, цитокин, матриксная металлопротеиназа, ischemic heart disease, diabetes, gene polymorphism, cytokine, matrix metalloproteinase

1. Дедов И. И., Шестакова М. В., Викулова О. К. Государственный регистр сахарного диабета в Российской популяции: статус 2014 года и перспективы развития. Сахарный диабет 2015;18 (3):5-22.

2. International Diabetes Federation. IDF Diabetes Atlas seventh edition. 2015. http://www.idf.org/idf-diabetes-atlas-seventh-edition

3. Дедов И. И., Шестакова М. В., Галстян Н. Р. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 7-й выпуск. Сахарный диабет 2015;18 (1S): 1-112

4. Strissel K.J., Denis G. V., Nikolajczyk B. S. Immune regulators of inflammation in obesity-associated type 2 diabetes and coronary artery disease. Curr Opin Endocrinol Diabetes Obes 2014;21 (5):330-338.

5. Schuett K. A., Lehrke M., Marx N., Burgmaier M. High-risk cardiovascular patients: clinical Features, Comorbidities, and Interconnecting Mechanisms. Front Immunol 2015;6:591.

6. Коненков В. И., Климонтов В. В. Ангиогенез и васкулогенез при сахарном диабете: новые концепции патогенеза и лечения сосудистых осложнений. Сахарный диабет 2012;15 (4):17-27

7. Парфенова Е. В., Ткачук В. А. Влияние гипергликемии на ангиогенные свойства эндотелиальных и прогениторных клеток сосудов. Вестник Российской академии медицинских наук 2012; (1):38-44

8. Takahashi H., Shibuya M. The vascular endothelial growth factor (VEGF ) /VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005;109 (3):227-241.

9. Tyan N. V., Klimontov V. V., Shevchenko A. V. et al. Polymorphisms in the gene promoters of IL4, IL6, IL10 and TNFA associated with serum levels of cytokines in type 2 diabetic subjects. Diabetologia 2016;59 (S1): S513.

10. Коненков В. И., Смольникова М. В. Структурные основы и функциональная значимость аллельного полиморфизма генов цитокинов человека и их рецепторов. Медицинская иммунология 2003;5 (1-2):11-28

11. Petrovic D., Verhovec R., Globocnik Petrovic M. et al. Association of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes. Cardiology 2007;107 (4):291-295.

12. Lin T. H., Wang C. L., Su H. M. et al. Functional vascular endothelial growth factor gene polymorphisms and diabetes: effect on coronary collaterals in patients with significant coronary artery disease. Clin Chim Acta 2010;411 (21-22):1688-1693.

13. Cui Q. T., Li Y., Duan C. H. et al. Further evidence for the contribution of the vascular endothelial growth factor gene in coronary artery disease susceptibility. Gene 2013;521 (2):217-221.

14. Galimudi R. K., Spurthi M. K., Padala C. et al. Interleukin 6 (-174G/C) variant and its circulating levels in coronary artery disease patients and their first degree relatives. Inflammation 2014;37 (2):314-321.

15. Sbarsi I., Falcone C., Boiocchi C. et al. Inflammation and atherosclerosis: the role of TNF and TNF receptors polymorphisms in coronary artery disease. Int J. Immunopathol Pharmacol 2007;20 (1):145-154.

16. Sobti R. C., Kler R., Sharma Y. P. et al. Risk of obesity and type 2 diabetes with tumor necrosis factor-а 308G/A gene polymorphism in metabolic syndrome and coronary artery disease subjects. Mol Cell Biochem 2012;360 (1-2):1-7.

17. Alp E., Menevse S., Tulmac M. et al. The role of matrix metallo-proteinase-2 promoter polymorphisms in coronary artery disease and myocardial infarction. Genet Test Mol Biomarkers 2011;15 (4):193-202.

18. Niu W., Qi Y. Matrix metalloproteinase family gene polymorphisms and risk for coronary artery disease: systematic review and metaanalysis. Heart 2012;98 (20):1483-1491.

19. Zhang F. X., Sun D. P., Guan N. et al. Association between -1562C>T polymorphism in the promoter region of matrix metalloproteinase-9 and coronary artery disease: a meta-analysis. Genet Test Mol Biomarkers 2014;18 (2):98-105.

20. Коненков В. И., Шевченко А. В., Прокофьев В. Ф. и др. Ассоциации вариантов гена фактора роста сосудистого эндотелия (VEGF) и генов цитокинов (IL1В, IL4, IL6, IL10, TNFA) c сахарным диабетом 2-го типа у женщин. Сахарный диабет 2012;15 (3):4-10

21. Winkler C., Krumsiek J., Lempainen J. et al. A strategy for combining minor genetic susceptibility genes to improve prediction of disease in type 1 diabetes. Genes Immun 2012; 13 (7):549-555.

22. Knüppel S., Meidtner K., Arregui M. et al. Joint effect of unlinked genotypes: application to type 2 diabetes in the EPIC-Potsdam case-cohort study. Ann Hum Genet 2015;79 (4):253-263.

23. Kim H. W., Ko G.J., Kang Y. S. et al. Role of the VEGF 936 C/T. polymorphism in diabetic microvascular complications in type 2 diabetic patients. Nephrology (Carlton) 2009;14 (7):681-688.

24. Климонтов В. В., Тян Н. В., Орлов Н. Б. и др. Взаимосвязь уровня фактора роста эндотелия сосудов в сыворотке крови и полиморфизма гена VEGFA с ишемической болезнью сердца у больных сахарным диабетом 2 типа. Кардиология 2017;57 (5):17-22

25. Briguori C., Testa U., Colombo A. et al. Relation of various plasma growth factor levels in patients with stable angina pectoris and total occlusion of a coronary artery to the degree of coronary collaterals. Am J. Cardiol 2006;97 (4):472-476.

26. Sun Z., Shen Y., Lu L. et al. Increased serum level of soluble vascular endothelial growth factor receptor-1 is associated with poor coronary collateralization in patients with stable coronary artery disease. Circ J. 2014;78 (5):1191-1196.